New Joint-Health Chewable Offers Alternative to Glucosamine and Chondroitin
The Flex Pro ES Chewables combine astaxanthin, hyaluronate, and hydrolyzed eggshell membrane.
Photo © iStockphoto.com/Raycat
For many of the top joint-health ingredients, including glucosamine and chondroitin, chewable products have historically proven difficult to work with due to undesirable tastes and other formulation issues. That’s fortunately not the case with the new Flex Pro ES Chewables from Valensa International (Orlando, FL), which combine astaxanthin, hyaluronate, and hydrolyzed eggshell membrane in “pleasant-tasting, sugar-free“ chewable tablets that target several key areas of joint health.
The Flex Pro ES Chewables formulation includes Zanthin natural astaxanthin, Fleuxron, a proprietary, “immune-stimulating type of Hylauronate,” and hydrolyzed eggshell membrane, which delivers collagen, elastin, and elastin precursors. The tablets are designed to enhance joint-tissue repair, support synovial fluid health, and provide antioxidants that target oxidative stress and issues related to chronic low-level inflammation, according to Valensa.
The tablets may be especially attractive for consumers who have trouble swallowing pills, including diabetics and seniors, explains Rudi E. Moerck, PhD, president and CEO of Valensa.
“Industry standard glucosamine [and] chondroitin–based products have not been successfully delivered as chewables to date, and many other leading joint-health ingredients have taste issues,” Moerck says. “Flex Pro ES Chewables offer a unique delivery system in the form of a great-tasting, sugar-free chewable tablet.”
The recommended usage level for Valensa’s new joint-health product is one chewable per day, although people may consume up to four chewable tablets per day in certain situations.
Read more:
Collagen Peptides Reduce Joint Inflammation, Support Cartilage Regeneration, Animal Study Suggests
Eggshell Membrane May Ease Osteoarthritis Pain, Stiffness
MSM and Boswellic Acids Comparable to Glucosamine for Osteoarthritis Relief, Study Says
Michael Crane
Associate Editor
Nutritional Outlook Magazine
michael.crane@ubm.com
Magnesium L-threonate, Magtein, earns novel food authorization in the European Union
December 19th 2024According to the announcement, the authorization is also exclusive to AIDP and its partner company and licensee, ThreoTech, meaning that they are the only parties that can market magnesium L-threonate in the EU for a period of five years.
Survey finds a lack of enthusiasm about AI technology among food and beverage consumers
December 12th 2024The survey, commissioned by Ingredient Communications and conducted by SurveyGoo, found that 83% of respondent agreed that companies should declare on product labels when a product has been designed or manufactured with the assistance of AI technology.
Kelker Pharma to launch nutritional support system for GLP-1 medication users that features TriBsyn
December 11th 2024B&D Nutritional Ingredients Inc., an exclusive distribution partner of CarnoSyn Brands and Natural Alternatives International Inc., announced that its customer, Kelker Pharma, will be launching the “first science-backed nutritional support system” for GLP-1 medication users, called Nutrilinq Genesis.
